The American Reporter
Wednesday, September 16, 2026
  • Login
  • World
  • National
  • Science
  • Business
  • Health
  • Education
  • Lifestyle
  • Entertainment
  • Sports
  • Technology
No Result
View All Result
  • World
  • National
  • Science
  • Business
  • Health
  • Education
  • Lifestyle
  • Entertainment
  • Sports
  • Technology
No Result
View All Result
The American Reporter
No Result
View All Result

Evan Zimmermann invests in Biotech start-up Altos Labs

The Moderna backer has invested alongside Amazon’s founder Jeff Bezos

James Boley by James Boley
January 12, 2022
in Business
Evan Zimmermann invests in Biotech start-up Altos Labs
621
VIEWS
Share on FacebookShare on Twitter

Evan Zimmermann has invested in trailblazer biotech firm Altos Labs. He is among a group of investors, along with Amazon’s founder Jeff Bezos and Israeli-Russian billionaire Yuri Milner. The exact amount invested by Zimmermann is not yet known.

Altos Labs is a crunch-based firm that utilizes biological reprogramming technology, a way to rejuvenate cells in the laboratory that could be extended to revitalize the entire body, thereby reversing the aging process and expanding the human lifespan.  The World’s richest man, Jeff Bezos, and biotech mogul Evan Zimmermann, have shown trust in this technology by investing in the firm.

Evan Zimmermann has been investing in biotech companies, some of which are now publicly-traded. Many of Zimmermann’s investments in this space are companies working on solutions for cancer. According to the WHO, cancer is the second leading cause of death. Cancer treatment remains an area with significant unmet medical need.

Zimmermann is best known for his early investment in Moderna, the biotech company that first developed a vaccine for COVID-19. He invested in Moderna when It was not as renowned a brand as it is today. Moderna’s success in bringing breakthrough vaccine for COVID-19 and its subsequent growth has also boosted Evan Zimmermann’s public profile as a biotech visionary.

Zimmermann also participated in the $76 million investment round for Nautilus Biotechnology in 2020. Nautilus has focused on tackling diseases like cancer and multiple sclerosis. It went public in February 2021 through a blank-check company called Arya Sciences Acquisition in a deal that valued it at $900 million.

He also participated in the funding of Sana Biotechnology which raised a massive $700 million from a group of investors including Evan Zimmermann in 2020. The company went public in February 2021 in a transaction that raised nearly $600 million.

The exact reason why Evan Zimmermann has decided to put money in Altos Labs is not clear. Obviously, as Zimmermann gets older, he might want to fund research that could help extend his longevity and quality of life. Altos Labs is indeed on a mission to help people live more active and comfortable lives.

Previous Post

Black Girl Magic: Meet Real Estate Sensation Quiana Watson

Next Post

Tribal Trap’s Stan Wittenberg Talks About Building A Record Label From Ground Zero

Next Post
Tribal Trap’s Stan Wittenberg Talks About Building A Record Label From Ground Zero

Tribal Trap’s Stan Wittenberg Talks About Building A Record Label From Ground Zero

Latest News

HKEX-listed chairman funded failed bid to uphold will that promised him HK$1.92 billion

HKEX-listed chairman funded failed bid to uphold will that promised him HK$1.92 billion

September 15, 2026

The Difference Between Looking Wealthy And Being Financially Resilient

September 11, 2026

Fratarcangeli Wealth Management: Why Election-Year Volatility Should Be Treated as Opportunity, Not Just Risk

September 10, 2026

Manmin Church Marks 25th Bible Quiz Contest

September 7, 2026

John Martinkat Discusses the Future of International Tax Planning

September 4, 2026

Why Enterprises Are Rethinking Data Security in the Age of AI Agents

September 3, 2026

Tajel Shah Discusses Building Effective SOPs: Foundational Strategies for Administrative Excellence

September 2, 2026

The Best Ballet Classes in Melbourne for 2026

September 2, 2026

MAXIMILIEN SCHMITT: “My creative path has been a fragile equilibrium between constant change and strong commitment.”

September 2, 2026

Denis Kitaev, his Rethinking of Luxury Living, and the Ideas Behind Vesper

September 2, 2026

The Moment Money Stops Feeling Like a Problem and Starts Feeling Like Power

September 1, 2026

Matthew Fleeger’s Investment Thesis on Downturns

September 1, 2026
  • Home
  • About Us
  • Our Staff
  • Contact Us
  • Privacy Policy
  • Editorial Policy
  • Use of Cookies

© 2019 - The American Reporter

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In
No Result
View All Result
  • Home
  • About Us
  • Our Staff
  • Contact Us
  • Privacy Policy
  • Editorial Policy
  • Use of Cookies

© 2019 - The American Reporter

This website uses cookies. By continuing to use this website you are giving consent to cookies being used. Visit our Privacy and Cookie Policy.